Exosomes derived from tumor adjacent fibroblasts efficiently target pancreatic tumors.
Desmoplasia
Exosomes
Extracellular vesicles
Ormeloxifene
Pancreatic cancer
Personalized medicine
Tumor adjacent normal tissue fibroblasts (NAF)
Tumor targeting
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
26
09
2023
revised:
25
01
2024
accepted:
26
01
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
19
7
2024
Statut:
ppublish
Résumé
The application of extracellular vesicles, particularly exosomes (EXs), is rapidly expanding in the field of medicine, owing to their remarkable properties as natural carriers of biological cargo. This study investigates utilization of exosomes derived from stromal cells of tumor adjacent normal tissues (NAF-EXs) for personalized medicine, which can be derived at the time of diagnosis by endoscopic ultrasound. Herein, we show that exosomes (EXs) derived from NAFs demonstrate differential bio-physical characteristics, efficient cellular internalization, drug loading efficiency, pancreatic tumor targeting and delivery of payloads. NAF-derived EXs (NAF-EXs) were used for loading ormeloxifene (ORM), a potent anti-cancer and desmoplasia inhibitor as a model drug. We found that ORM maintains normal fibroblast cell phenotype and renders them incompatible to be triggered for a CAF-like phenotype, which may be due to regulation of Ca
Identifiants
pubmed: 39027237
doi: 10.1016/j.apsb.2024.04.003
pii: S2211-3835(24)00131-X
pmc: PMC11252470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3009-3026Informations de copyright
© 2024 The Authors.